Skip to main content

Table 2 Intercenter characteristics a

From: Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: a multicentric study

Characteristics Center 1 (N = 82) Center 2 (n = 124) Center 3 (n = 161) P -value b
AD patients     
  Number of subjects (%) 37 (45.1) 73 (58.9) 50 (31.1) <0.001
  Age (yr), mean (SD) 68.9 (8.6) 67.0 (9.5) 68.5 (10.7) 0.54
  Women, n (%) 27 (73.0) 39 (53.4) 31 (62.0) 0.14
  MMSE, mean (SD) 18.6 (6.5) 19.5 (6.3) 22.8 (4.9) 0.003
  CSF biomarkers, pg/ml, mean (SD)     
   Total tau 599.5 (281.2) 774.2 (370.7) 539.6 (315.2) <0.001
   p-tau181 79.4 (24.4) 101.5 (42.2) 80.0 (39.2) 0.002
   Aβ42 656.9 (257.1) 603.2 (245.4) 772.5 (363.5) 0.008
   Aβ40 16,229.7 (6,252.8) 13,426.8 (5,250.9) 20,814.3 (12,114.6) <0.001
   Aβ 42/40 0.044 (0.018) 0.049 (0.021) 0.045 (0.025) 0.39
Non-AD patients     
  Number of subjects (%) 45 (54.9) 51 (41.1) 111 (68.9) <0.001
  Age (yr), mean (SD) 63.3 (10.7) 64.4 (10.6) 65.0 (11.8) 0.70
  Women, n (%) 17 (37.8) 20 (40.0) 56 (50.4) 0.25
  MMSE, mean (SD) 23.7 (4.9) 20.9 (6.1) 24.7 (5.3) <0.001
  CSF biomarkers (pg/ml), mean (SD)     
   Total tau 201.5 (64.0) 283.8 (150.5) 308.6 (248.6) 0.01
   p-tau181 40.4 (12.8) 46.2 (15.8) 40.8 (19.7) 0.14
   Aβ42 984.3 (253.6) 987.0 (344.7) 1,039.3 (343.3) 0.50
   Aβ40 12,219.5 (4,775.2) 11,161.0 (4,955.5) 17307.2 (9,952.7) <0.001
   Aβ 42/40 0.087 (0.024) 0.098 (0.041) 0.077 (0.066) 0.06
  1. aAβ, Amyloid-beta; AD, Alzheimer’s disease; CSF, Cerebrospinal fluid; MMSE, Mini Mental State Examination; p-tau181, tau phosphorylated at threonine 181; SD, Standard deviation. bBy χ2 test or analysis of variance.